Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- relation label "URI of the relation type" assertion.
- assertion label "Expressing a general claim with a super-pattern" assertion.
- activity label "Formalization-Activity" assertion.
- source label "URI of the source used by this formalization activity" assertion.
- creator label "ORCID identifier of the person who performed the formalization" assertion.
- quote label "source quote" assertion.
- assertion label "Derived from a formalization activity" assertion.
- source label "URI of the source used by this formalization activity" assertion.
- creator label "ORCID identifier of the person who performed the formalization" assertion.
- activity label "Formalization-Activity" assertion.
- quote label "source quote" assertion.
- assertion label "Generated by a formalization activity" assertion.
- subjectClass label "URI of the subject class (A)" assertion.
- contextClass label "URI of the context class" assertion.
- relation label "URI of the relation type" assertion.
- label label "informal label or text for the whole superpattern instance" assertion.
- qualifier label "URI of the qualifier" assertion.
- objectClass label "URI of the object class (B)" assertion.
- spi label "SPI:" assertion.
- assertion label "Expressing a general claim with a super-pattern" assertion.
- class1 label "URI of existing class 1" assertion.
- class2 label "URI of existing class 2" assertion.
- list label "List" assertion.
- newclass label "short ID of the new class" assertion.
- list-rest label "List-Rest" assertion.
- description label "description of the class" assertion.
- name label "the name of the class" assertion.
- assertion label "Defining a new class" assertion.
- description label "description of the class" assertion.
- list label "List" assertion.
- list-rest label "List-Rest" assertion.
- class2 label "URI of existing class 2" assertion.
- newclass label "short ID of the new class" assertion.
- class1 label "URI of existing class 1" assertion.
- name label "the name of the class" assertion.
- assertion label "Defining a new class by intersection or union" assertion.
- description label "description of the class" assertion.
- class1 label "URI of existing class 1" assertion.
- class2 label "URI of existing class 2" assertion.
- list label "List" assertion.
- list-rest label "List-Rest" assertion.
- name label "the name of the class" assertion.
- intersectionOrUnion label "select intersection or union" assertion.
- newclass label "short ID of new class" assertion.
- assertion label "Defining a new class by intersection or union" assertion.
- zonmw-covid label "ZonMw-COVID-19 Programme" assertion.
- cohort label "Elderly" assertion.
- association label "Currently, no medication has been approved for use in the USA for cognition in DLB but there is class I evidence suggesting that donepezil and rivastigmine improve cognition and global function [13, 14•]." assertion.
- step label "My awesome step to add " assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- step label "Step to add text (awesome world!) into an image" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- association label "Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD." assertion.
- cohort label "Adults" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "Attention deficit-hyperactivity disorder" assertion.
- MONDO_0007743 label "attention-deficit/hyperactivity disorder (ADHD)" assertion.
- MONDO_0007743 label "attention-deficit/hyperactivity disorder (ADHD)" assertion.
- MONDO_0007743 label "attention-deficit/hyperactivity disorder (ADHD)" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- association label "Ramelteon is a synthetic melatonin receptor agonist with high affinity for the MT1 and MT2 receptors, and is approved by the FDA for use in adults. Only few case reports have been published in children with NDDs reporting in general limited efficacy on night awakenings" assertion.
- cohort label "Children" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Paroxetine is not FDA approved for use in children and adolescents less than 18 years of age; however, clinicians do use off-label in this group." assertion.
- association label "Paroxetine is not FDA approved for use in children and adolescents less than 18 years of age; however, clinicians do use off-label in this group." assertion.
- cohort label "adults" assertion.
- MONDO_0000690 label "body dismorphic disorder" assertion.
- association label "Paroxetine is not FDA approved for use in children and adolescents less than 18 years of age; however, clinicians do use off-label in this group." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "There are other off-label uses of imipramine as in the treatment of chronic neuropathic pain and panic disorder." assertion.
- cohort label "Adults" assertion.
- association label "This profile suggests that asenapine may be of particular value off label for bipolar depression, anxiety, and aggression." assertion.
- cohort label "Children" assertion.
- association label "Diphenhydramine is the most commonly used and is a competitive H1-histamine receptor blocker" assertion.
- association label "Other antihistaminines have been used: trimeprazine was used in 22 children with night awakenings showing a moderate improvement (France, Blampied, & Wilkin- son, 1999); niaprazine (1 mg/kg in a single dose at bedtime) showed a decrease of sleep onset latency and an increase of sleep duration (Ottaviano, Gian- notti, & Cortesi, 1991) even if compared with benzo- diazepines (Montanari, Schiaulini, Covre, Steffan, & Furlanut, 1992)." assertion.
- cohort label "Children" assertion.
- cohort label "Children" assertion.
- association label "Based on available data, clonazepam may represent a treatment option in children with arousal disorders (parasomnias) or periodic leg movement disorder or restless legs syndrome (RLS), but future trials focused on objective sleep measures and safety issues are needed." assertion.